Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

152. Sequelae of Deformity in Adults With Brachial Plexus Birth Injuries
Liebrand, Rachida, Spinner, Robert J. , Bishop, Allen T., Shin, Alexander Y. , Bishop, Allen T. , Pulos, Nicholas

Plastic and Reconstructive Surgery - Global Open | May 1, 2025 | Volume: 13 | Issue: S1 | Pages: 105-105

10.1097/01.gox.0001112556.94441.cb Get It

AI-Powered Object Detection in Radiology: Current Models, Challenges, and Future Direction
Elhanashi, Abdussalam , Zheng, Qinghe , Almutairi, Nawal , Singh, Yashbir , Kuanar, Shiba , Ali, Farzana , Ünal, Orhan , Faghani, Shahriar , Zheng, Qinghe , Almutairi, Nawal , Singh, Yashbir , Ali, Farzana , Unal, Orhan , Faghani, Shahriar , Saponara, Sergio , Zheng, Qinghe

Journal of Imaging | May 1, 2025 | Volume: 11 | Issue: 5 | Pages: 141

10.3390/jimaging11050141 | PMID 40422999 Get It

Artificial intelligence (AI)-based object detection in radiology can assist in clinical diagnosis and treatment planning. This article examines the AI-based object detection models currently used in many imaging modalities, including X-ray Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and Ultrasound (US). The key models from the convolutional neural network (CNN) as well as the contemporary transformer and hybrid models are analyzed based on their ability to detect pathological features, such as tumors, lesions, and tissue abnormalities. In addition, this review offers a closer look at the strengths and weaknesses of these models in terms of accuracy, robustness, and speed in real clinical settings. The common issues related to these models, including limited data, annotation quality, and interpretability of AI decisions, are discussed in detail. Moreover, the need for strong applicable models across different populations and imaging modalities are addressed. The importance of privacy and ethics in general data use as well as safety and regulations for healthcare data are emphasized. The future potential of these models lies in their accessibility in low resource settings, usability in shared learning spaces while maintaining privacy, and improvement in diagnostic accuracy through multimodal learning. This review also highlights the importance of interdisciplinary collaboration among artificial intelligence researchers, radiologists, and policymakers. Such cooperation is essential to address current challenges and to fully realize the potential of AI-based object detection in radiology.
Molecular Profiling of Nasopharyngeal Carcinoma Using the AACR Project GENIE Repository
Hsia, Beau , Sure, Asritha , Dongre, Roshan , Jo, Nicolas J. , Kuzniar, Julia , Bitar, Gabriel , Alshaka, Saif, Kim, Jeeho D. , Valencia‐Sanchez, Bastien A. , Brandel, Michael G. , Sato, Mariko , Levy, Michael L. , Polster, Sean P. , Patel, Vijay A. , Valencia, Bastien A. , Alshaka, Saif A , Polster, Sean P , Patel, Vijay A , Brandel, Michael G , Sato, Mariko , Hsia, Beau , Crawford, John Ross

Cancers | May 1, 2025 | Volume: 17 | Issue: 9 | Pages: 1544

10.3390/cancers17091544 | PMID 40361470 Get It

Background: Nasopharyngeal carcinoma (NPC) is a rare head and neck cancer arising from the mucosal lining of the nasopharynx, for which systemic therapeutic options remain scarce, reflecting the limited characterization of its genomic profile. This study utilized a large patient-level genomic repository to characterize genetic alterations, identify potential therapeutic targets, and improve disease modeling in NPC. Methods: A retrospective analysis of NPC samples was conducted using the AACR Project GENIE database. Targeted sequencing data were analyzed for recurrent somatic mutations, tumor mutational burden, and chromosomal copy number variations, with significance set at p < 0.05. Results: Frequent mutations were identified in KMT2D (20%), TP53 (16%), CYLD (9.6%), NFKBIA (6.4%), and PIK3CA (5.6%), implicating the p53, NF-κB, and PI3K pathways in NPC development. Notably, significantly distinct mutational profiles were observed based on both sex and race, with female patients exhibiting higher frequencies of PIK3C2G, ETV6, and CDKN1B mutations and non-Asian patients showing enrichment in KDM5A, CCND2, and TP53 mutations. Conclusions: This study presents a detailed genomic profile of NPC, identifying key mutations within established cancer-associated pathways. The identification of frequently mutated pathways (p53, NF-κB, and PI3K) suggests potential targets for novel therapies. Furthermore, distinct mutational landscapes in female and Asian NPC patients offer possibilities for precision therapeutic interventions.
Differences in Alzheimer's disease blood biomarker stability: Implications for the use of tau/amyloid ratios
Schuder, Bethany J., Ashrafzadeh‐Kian, Susan , Gronquist, Tina, Bornhorst, Joshua A. , Algeciras‐Schimnich, Alicia , Algeciras-Schimnich, Alicia , Figdore, Daniel J. , Ashrafzadeh-Kian, Susan, Bornhorst, Joshua

Alzheimer's & Dementia | May 1, 2025 | Volume: 21 | Issue: 4 | Pages: No page available

10.1002/alz.70173 | PMID 40308118 Get It

AbstractINTRODUCTIONWe compare the stability of phosphorylated tau (p‐tau)217, amyloid beta (Aβ)42, Aβ40, Aβ42/40, and p‐tau217/Aβ42 at different storage temperatures.METHODSTen ethylenediaminetetraacetic acid–plasma sample aliquots stored at frozen, refrigerated, and ambient temperatures were tested at various timepoints up to 30 days. The mean percent change from baseline was calculated.RESULTSAβ42 and Aβ40 concentrations decreased by >15% after 6 hours at ambient temperature and after 24 hours refrigerated, while p‐tau217 remained stable over 72 hours with < 10% deviation from baseline at either storage temperature. The Aβ42/40 ratio remained relatively constant as each analyte concentration decreased concurrently, while the p‐tau217/Aβ42 ratio deviated from baseline over time. All biomarkers were stable up to 30 days frozen.DISCUSSIONDifferences in the stability of Aβ42 and p‐tau217 may lead to altered p‐tau217/Aβ42 ratio results if samples are not handled properly during the pre‐analytical testing phase. Ideally, samples should be frozen promptly and sent to the laboratory frozen.Highlights Plasma phosphorylated tau (p‐tau)217, amyloid beta (Aβ)42, Aβ40, Aβ42/40, and p‐tau217/Aβ42 stability was assessed. P‐tau217 was stable, but Aβ42 and Aβ40 started decreasing by 6 hours at ambient temperature. The analyte stability differences led to falsely increased p‐tau217/Aβ42 ratios. Increases > 15% were seen in p‐tau217/Aβ42 after 6 hours at ambient temperature or 24 hours at 4°C.
Stress Echo 2030 Study: A Flagship Project of the Italian Society of Echocardiography and Cardiovascular Imaging
Picano, Eugenio, Padang, Ratnasari , Kane, Garvan C. , Villarraga, Hector R. , Arruda‐Olson, Adelaide M. , Vazquez, Jesus Peteiro , Boshchenko, A , Журавлева, О. А. , Sviazova, Natalia , Balkevičienė, Laura, Djordjevic‐Dikic, Ana , Kobal, Sergio , Lisi, Matteo , Merli, Elisa , Manganelli, F, Daros, Clarissa Borguezan , D’Alfonso, Maria Grazia , Mori, Fabio , Kasprzak, Jarosław D. , Safarova, Ayten, Timofeeva, T. N. , Mosto, Hugo , Wierzbowska‐Drabik, Karina , Ratanasit, Nithima , Colonna, Paolo , Ostojić, Miodrag , Cortigiani, Lauro , Rigo, Fausto , Benfari, Giovanni , Soulis, Dimitrios , Yin, Lixue , Mazzi, Alberto, Haber, Diego M. Lowenstein, Marconi, Sofia, Tripepi, Giovanni Luigi, Nes, Michele De, Bartolacelli, Ylenia , Villari, Bruno, Wierzbowska-Drabik, Karina , Kasprzak, Jaroslaw D , Benfari, Giovanni , Colonna, Paolo , Boshchenko, Alla , Ciampi, Quirino , Arbucci, Rosina , Zagatina, A , Kalinina, Elena , Ryabova, Tamara , Čelutkienė, Jelena , Saad, Ariel K. , Bursi, Francesca , Rodríguez‐Zanella, Hugo , Gaibazzi, Nicola , Costantino, Marco Fabio , Kovačević-Preradović, Tamara , Varga, Albert , Nikolic, Aleksandra, Cocchia, Rosangela , Pálinkás, Attila , Pálinkás, Eszter Dalma , Valente, Filipa Xavier , Wang, Yi , Heyning, Caroline M. Van De , Mazzi, Alberto, Lowenstein, Jorge , Barbieri, Andréa , Mantovani, Francesca , Pepi, Mauro , Carerj, Scipione , Pellikka, Patricia A.

Journal of Cardiovascular Echography | May 1, 2025 | Volume: 35 | Issue: 1 | Pages: 1-7

10.4103/jcecho.jcecho_2_25 | PMID 40463758 Get It

Over the past decade, stress echocardiography has evolved from a test for assessing epicardial artery stenosis to a comprehensive functional test, targeting multiple cardiovascular parameters. The new approach includes several structured steps: (a) evaluating regional wall motion abnormalities to detect epicardial artery stenosis or vasospasm; (b) assessing pulmonary congestion and diastolic function via B-lines with lung ultrasound; (c) gauging preload and contractile reserve with volumetric echocardiography; (d) measuring coronary microvascular reserve using Doppler-based coronary flow velocity in the middistal left anterior descending artery; and (e) determining cardiac sympathetic reserve by tracking heart rate reserve on an ECG. This evolution was supported extensively by the Italian Society of Echocardiography and Cardiovascular Imaging (SIECVI), which played a key role in five areas: (1) developing the initial, curiosity-driven project; (2) disseminating protocols and results at national and international conferences, supporting logistic infrastructure and publication expenses; (3) establishing a digital platform (customized Redcap) for data entry and storage; (4) facilitating patient recruitment across 19 Italian centers; and (5) offering formal endorsement through six presidencies, adding credibility and reach beyond any single institution. The protocol quickly advanced from concept to high-impact publications, earning inclusion in 2024 specialty guidelines. Initially Italian-led, the study now includes 50 centers across 20 countries (e.g. USA and China). Beyond the 50 peer-reviewed papers published in 2016–2024, this study offers a novel, sustainable approach to cardiac stress testing, providing more information at lower costs, with zero radiation and minimal environmental impact. SIECVI’s endorsement was instrumental in amplifying the study’s rigor and outreach.
Plicating the Gut: Endoscopic Suturing to Resolve Ileal Intussusception Causing Ileocolic Anastomotic Obstruction
Chopra, Preeyati , Ohri, Ashwariya , Buttar, Navtej , Ohri, Ashwariya , Buttar, Navtej S, Goyal, Mayank

ACG Case Reports Journal | May 1, 2025 | Volume: 12 | Issue: 5 | Pages: e01662

10.14309/crj.0000000000001662 | PMID 40309559 Get It

Impact of glucagon-like peptide-1 receptor agonists on hypertension management: a narrative review
Oliveira-Gomes, Diana De , Pingili, Adhvithi , Inglis, Sara S. , Mandras, Stacy A. , De Oliveira-Gomes, Diana, daSilva-deAbreu, Adrian, Inglis, Sara S , Loro-Ferrer, Juan Francisco , daSilva‐deAbreu, Adrian

Current Opinion in Cardiology | May 1, 2025 | Volume: 40 | Issue: 4 | Pages: 185-192

10.1097/hco.0000000000001225 | PMID 40305149 Get It

Purpose of review The increasing prevalence of hypertension, alongside the growing use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for conditions beyond type 2 diabetes, underscores the need for understanding if there is a role for these medications in blood pressure management. This review addresses the timely opportunity to assess how GLP-1 RAs could influence blood pressure control, potentially broadening therapeutic strategies for cardiovascular risk management. Recent findings Emerging literature indicates that GLP-1 RAs influence blood pressure through various mechanisms, such as sympathetic nervous modulation, vasodilation, and diuretic effects. Clinical trials demonstrate modest yet statistically significant reductions in systolic blood pressure (SBP), with less consistent effects on diastolic blood pressure (DBP). The advent of dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists presents enhanced possibilities for managing hypertension. Summary The implications of these findings suggest that GLP-1 RAs have potential as adjunctive therapies for hypertension, especially in patients already receiving these agents for other cardiometabolic conditions. The blood pressure-lowering effects, often independent of weight loss or glucose control, warrant further investigation to determine their precise role within hypertension treatment algorithms and encourage integration into clinical practice.
Global patterns of utilization of noninvasive tests for the clinical management of metabolic dysfunction–associated steatotic liver disease
Lazarus, Jeffrey V., Alkhouri, Naim , Noureddin, Mazen, Wong, Vincent Wai-Sun, Tsochatzis, Emmanuel , Avila, Leyla de , Racila, Andrei, Nader, Fatema, Stepanova, Maria, Younossi, Zobair M. , Lazarus, Jeffrey V. , Lazarus, Jeffrey V , Tsochatzis, Emmanuel A , Allen, Alina M. , Noureddin, Mazen , Wong, Vincent Wai‐Sun , Mark, Henry E. , Henry, Linda L , Castera, Laurent

Hepatology Communications | May 1, 2025 | Volume: 9 | Issue: 5 | Pages: No page available

10.1097/hc9.0000000000000678 | PMID 40304566 Get It

Background: Noninvasive tests (NITs) are used to risk-stratify metabolic dysfunction–associated steatotic liver disease. The aim was to survey global patterns of real-world use of NITs. Methods: A 38-item survey was designed by the Global NASH Council. Providers were asked about risks for advanced fibrosis, which NITs (cutoff values) they use to risk-stratify liver disease, monitor progression, and which professional guidelines they follow. Results: A total of 321 participants from 43 countries completed the survey (54% hepatologists, 28% gastroenterologists, and 18% other). Of the respondents, 85% would risk-stratify patients with type 2 diabetes, obesity (82%), or abnormal liver enzymes (73%). Among NITs to rule out significant or advanced fibrosis, transient elastography (TE) and fibrosis-4 (FIB-4) were most used, followed by NAFLD Fibrosis Score, Enhanced Liver Fibrosis, and magnetic resonance elastography. The cutoffs for ruling out significant fibrosis varied considerably between practices and from guidelines, with only 50% using TE <8 kPa, 65% using FIB-4 <1.30 for age <65, and 41% using FIB-4 <2.00 for age ≥65. Similar variability was found for ruling in advanced fibrosis, where thresholds of FIB-4 ≥2.67 and TE ≥10 kPa were used by 20% and 17%, respectively. To establish advanced fibrosis, 48% would use 2 NITs while 23% would consider 1 NIT, and 17% would confirm with liver biopsy. TE was used by >75% to monitor, and 66% would monitor (intermediate or high risk) annually. Finally, 65% follow professional guideline recommendations regarding NITs. Conclusions: In clinical practice, there is variability in NIT use and their thresholds. Additionally, there is suboptimal adherence to professional societies’ guidelines.
Adolescents' and young adults' reactions to and perceived utility of carrier screening results in the context of a genomic research study
Grimes, H , McGowan, Michelle L. , Sinclair, Jessica , Prows, Cynthia A. , Lipstein, Ellen A. , Myers, Melanie F. , Grimes, Haley N , Sinclair, Jessica A, Myers, Melanie F

Journal of Genetic Counseling | May 1, 2025 | Volume: 34 | Issue: 3 | Pages: No page available

10.1002/jgc4.70027 | PMID 40305233 Get It

AbstractAlthough guidelines have historically recommended deferring decisions about learning genomic information for conditions not actionable in childhood until adulthood, youth have increasing access to personal genomic information through research, clinical, and direct‐to‐consumer testing. However, little is known about young people's reactions to, and perceived future utility of learning genomic information actionable in adulthood. We conducted qualitative interviews with 28 youth ages 15–22 without clinical indications for genetic screening who, through enrollment in a genomic decision‐making research study, learned they were carriers of an autosomal recessive condition, or anticipated being carriers but received negative results. Semi‐structured interviews occurred virtually between 3 and 16 months after the return of results. Interpretative description guided deductive and inductive coding of transcripts. Of the 28 participants, 21 received positive carrier results, and 7 received negative results. Although some carriers felt the result was unexpected, they expressed relief overall and did not feel worried about their result. Participants with negative results also felt relief about their results. All participants correctly described what a carrier result means, but some carriers could not remember the condition associated with their result. No participant regretted learning personal genomic information, and all reported their results helped them better understand risks to future children. Carriers who perceived the condition for which they were carriers as more severe and/or those familiar with the condition were more likely to remember their result and consider future reproductive options. Carriers also felt testing at their respective age allowed increased familiarity with results and more time to gather information and decide on the personal utility of the information. Our findings suggest early access to genomic information for some youth may allow integration of carrier information over time with minimal adverse effects. More research is needed to assess long‐term outcomes among carriers.
Pharmacologic features, clinical applications, and drug safety evaluation of futibatinib in the treatment of biliary tract cancer (BTC)
Pirozzi, Angelo , Hoyek, Celine , Okano, Naohiro , Rimassa, Lorenza, Usón, Pedro Luiz Serrano , Bekaii-Saab, Tanios S , Rimassa, Lorenza , Abidoye, Oluseyi , Sonbol, Mohamad Bassam , Uson, Pedro L S , Rimassa, Lorenza , Bekaii‐Saab, Tanios , Borad, Mitesh J.

Expert Opinion on Drug Safety | May 1, 2025 | Volume: 24 | Issue: 12 | Pages: 1383-1390

10.1080/14740338.2025.2495178 | PMID 40307985 Get It